22.11.2016 • News

DuPont Supplies Enzymes to Miavit

(c) photosbyjim/Getty Images
(c) photosbyjim/Getty Images

DuPont Industrial Biosciences will supply its Fibrezyme G4 enzymes to Miavit, a German provider of feedstuffs, supplement, minerals and vitamins. Miavit will use the enzymes in MiaMethan ProCut, its new biogas ingredient for the agricultural sector. Fibrezyme G4 is said to help reduce the viscosity of poorly digestible materials by more than 60%, thus allowing faster processing time.

“As new technology like Fibrezyme comes online, we see tremendous opportunity for our customers to improve efficiency and yields. This, in turn, provides the emerging biogas industry a new revenue stream, particularly for rural and farm communities, from materials that would ordinarily go to waste – reducing damaging environmental impacts and expanding renewable options for power generation,” said Franz Otten, Miavit’s managing director of sales.

Enzymes work by accelerating the breakdown of various materials, such as plant fibers and animal and food waste, into sugars and amino acids, which are more suitable for conversion into biogas. Methane biogas is primarily used to generate renewable electricity, or is compressed and inserted into the gas pipeline grid.

DuPont entered the growing biogas sector in July of this year with the launch of Optimash AD-100, a liquid enzyme that can increase biogas yields in anaerobic digesters by as much as 13%. Fibrezyme G4 was originally launched by Florida-based biotechnology company Dyadic in April 2014. Dyadic sold its industrial technology assets to DuPont Industrial Biosciences for $75 million in January 2016, having decided to focus exclusively on its biopharmaceutical business.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read